Labaran Waya

Sabon Rigakafin Rigakafi don Cutar Alzheimer Ana samun Tallafin

Written by edita

Cibiyar Nazarin Magungunan Kwayoyin Halitta (IMM), ƙungiya mai zaman kanta da aka sadaukar don bincike na asali da fassarar kwayoyin halitta don samar da lafiya, ingantattun alluran rigakafin cutar Alzheimer da sauran cututtukan neurodegenerative, a yau ta sanar da cewa an ba ta kyautar dala miliyan 12 daga Cibiyar National Institute on. Tsufa (NIA) sashen Cibiyar Kiwon Lafiya ta Amurka (NIH) don tallafawa gwaje-gwajen asibiti na maganin rigakafin beta-amyloid (Aβ) wanda ya dogara da DNA (AV-1959D) da furotin recombinant (AV-1959R) don rigakafin cutar Alzheimer (AD). Tare da haɗin gwiwar Jami'ar California, Irvine (Babban Bincike, David Sultzer, MD) da Jami'ar Kudancin California (Babban Bincike, Lon Schneider, MD), IMM (Babban Bincike da lambar NIH, Michael Agadjanyan, Ph.D.) yana tsammanin. don fara nazarin asibiti na Mataki na 1 a cikin Amurka a cikin kwata na biyu na 2022.            

Har ya zuwa yanzu, magungunan AD sun fi mayar da hankali kan kula da cututtukan da ke ciki bayan cutar ta kama. Duk da haka, da zarar ilimin cututtuka ya fara kuma kwayoyin neurons sun lalace, ya zama ba zai yiwu a dakatar da cutar ba. Bayanai na yanzu sun nuna cewa rigakafin rigakafin da aka yi kafin kamuwa da cuta zai iya hana haɗuwar Aβ kuma yana jinkirta AD sosai.

"Aβ yana da muhimmiyar rawa a cikin tsarin da AD ke tasowa," in ji Dokta Agadjanyan, Mataimakin Shugaban IMM da Shugaban Sashen Immunology. "Bayanan bayanan da aka buga, tare da sakamakon asibiti da aka samu tare da ƙwayoyin rigakafin anti-Aβ na monoclonal, suna ba da shawarar cewa rigakafin kawai na iya jinkirta ko ma dakatar da AD. Saboda buƙatar gudanarwa na wata-wata na babban adadin ƙwayoyin rigakafi na monoclonal anti-Aβ, ba shi da amfani a yi amfani da su don rigakafin rigakafin mutane masu lafiya cikin haɗarin AD. Sabanin haka, tsarin rigakafin mu na ƙarin, wanda ya ƙunshi AV-1959D a matsayin babban rigakafin rigakafi da AV-1959R a matsayin rigakafin haɓakawa, na iya haifar da manyan matakan rigakafi waɗanda ke hana haɗuwar Aβ da jinkirta fara cutar a cikin mutanen da ba su da rauni a cikin haɗarin AD. ”

Nazarin da aka buga akan duka alluran AV-1959D da AV-1959R sun nuna cewa suna da lafiya kuma suna da rigakafi a cikin mice, zomaye da waɗanda ba na ɗan adam ba. Waɗannan alluran rigakafin sun dogara ne akan fasahar dandali na MultiTEP na musamman da aka ba da izini ga Nuravax, wanda zai kula da tallace-tallace, haɓaka haɗin gwiwa da yarjejeniyoyin ba da lasisi tare da kamfanonin biopharmaceutical.

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...